Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - AB 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 199769.16 
• Atom Count: 7700 
• Residue Count: 1735 
• Unique protein chains: 2

5M6U

HUMAN PI3KDELTA IN COMPLEX WITH LASW1579

• DOI: 10.2210/pdb5M6U/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda


• Deposited: 2016-10-26 Released: 2017-02-01 
• Deposition Author(s): Segarra, V., Hernandez, B., Lozoya, E., Blaesse, M., Hoeppner, S., Jestel, A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.85 Å
• R-Value Free: 0.309 
• R-Value Work: 0.256 

Literature

Discovery of a Potent, Selective, and Orally Available PI3K delta Inhibitor for the Treatment of Inflammatory Diseases.

Erra, M., Taltavull, J., Greco, A., Bernal, F.J., Caturla, J.F., Gracia, J., Dominguez, M., Sabate, M., Paris, S., Soria, S., Hernandez, B., Armengol, C., Cabedo, J., Bravo, M., Calama, E., Miralpeix, M., Lehner, M.D.

(2017) ACS Med Chem Lett 8: 118-123

• PubMed: 28105286 
• DOI: 10.1021/acsmedchemlett.6b00438


• PubMed Abstract: 
  

The delta isoform of the phosphatidylinositol 3-kinase (PI3Kδ) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases. Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kδ inhibitors is described. The main challenge of the optimization process was to identify an orally available compound with a good pharmacokinetic profile in preclinical species that predicted a suitable dosing regimen in humans. Structure-activity relationships and structure-property relationships are discussed. This medicinal chemistry exercise led to the identification of LAS191954 as a candidate for clinical development.

---

Organizational Affiliation: 

Medicinal Chemistry and Screening, Pharmacokinetics and Metabolism, Systems Biology, and Respiratory Therapeutic Area, Almirall R&D , Barcelona 08980, Spain.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	A	1011	Homo sapiens	Mutation(s): 0  Gene Names: PIK3CD EC: 2.7.1.153
Find proteins for O00329 (Homo sapiens) Go to Gene View: PIK3CD Go to UniProtKB:  O00329

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
Phosphatidylinositol 3-kinase regulatory subunit alpha	B	724	Homo sapiens	Mutation(s): 0  Gene Names: PIK3R1 (GRB1)
Find proteins for P27986 (Homo sapiens) Go to Gene View: PIK3R1 Go to UniProtKB:  P27986

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
7KA	A	4-azanyl-6-[[(1~{S})-1-(4-oxidanylidene-3-phenyl-pyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino]pyrimidine-5-carbonitrile C19 H16 N8 O MDMKWYWCJZMADI-LBPRGKRZSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.85 Å
• R-Value Free: 0.309 
• R-Value Work: 0.256 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 92.493	α = 90.00
b = 113.212	β = 90.00
c = 144.321	γ = 90.00

Software Package:

Software Name	Purpose
PHASER	phasing
PDB_EXTRACT	data extraction
SCALA	data scaling
XDS	data reduction
REFMAC	refinement

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2016-10-26 
• Released Date: 2017-02-01 
• Deposition Author(s): Segarra, V., Hernandez, B., Lozoya, E., Blaesse, M., Hoeppner, S., Jestel, A.

Revision History 

• Version 1.0: 2017-02-01
  Type: Initial release
• Version 1.1: 2019-03-06
  Type: Data collection